Ocugen, Inc. Files SEC Form D Notification for Security Sale

Strategic Insights -

Ocugen, Inc., a biopharmaceutical company, has submitted a U.S. Securities and Exchange Commission (SEC) filing, specifically Form D, on May 7, 2020. The filing notifications the sale of securities by the company, which is required under Regulation D or Section 4(6) exemptions from the registration provisions of the Securities Act of 1933. The Form D submission provides contact information for Ocugen, Inc., including the company's address and phone number.

Key Takeaways:

  • Ocugen, Inc. is a biopharmaceutical company that submitted a SEC Form D notification for the sale of securities.
  • The filing was made on May 7, 2020, and is a requirement under Regulation D or Section 4(6) exemptions from the Securities Act of 1933.
  • The company's SIC code is 2836, Biological Products, and the SEC file number is 0001192482-20-000312.
  • Ocugen, Inc. has a physical address at 5 Great Valley Parkway, Suite 160, Malvern, PA 19355, and a phone number of 484-328-4698.
  • The company's filing is publicly available on the SEC website, at http://www.sec.gov/Archives/edgar/data/1372299/0001192482-20-000312-index.html.
  • The Form D submission provides notice of the sale of securities by Ocugen, Inc., and is a requirement under Regulation D exemptions.
  • The company's filing is related to biopharmaceutical industry and healthcare biotechnology companies.

Statistics:

  • May 7, 2020: Date of SEC Form D filing submission by Ocugen, Inc.
  • 2836: SIC code for Biological Products, which Ocugen, Inc. operates under.
  • 0001192482-20-000312: SEC file number for Ocugen, Inc.'s Form D filing.
  • 15: Number of days after the first sale of securities that a Form D filing must be submitted to the SEC.

Sources:

  • U.S. Securities and Exchange Commission (SEC) filing by Ocugen, Inc. (Form D)
  • NewsRx journalists, Washington, D.C. (Publication Date: May 25, 2020)
  • Regulation D and Section 4(6) exemptions from the Securities Act of 1933
  • SEC filing website: http://www.sec.gov/Archives/edgar/data/1372299/0001192482-20-000312-index.html
  • Biotech Business Week, NewsRx (Publication Date: May 25, 2020)